Radioactive drug trial seeks to target advanced kidney cancer
NCT ID NCT06649682
Summary
This early-stage study is testing a new two-part radioactive drug for people with advanced kidney cancer that has spread. First, a low-dose version is used for imaging to see where tumors are. Then, a higher-dose version is given as a treatment to try to control the cancer. The main goal is to find a safe dose and see how well the body handles it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.